Trials / Terminated
TerminatedNCT04975256
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
A Phase 1/1b Trial of MRTX849 in Combination With BI 1701963 in Patients With Advanced Solid Tumors With KRAS G12C Mutation
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate safety, tolerability, drug levels, molecular effects and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors that have a KRAS G12C mutation.
Detailed description
This study will evaluate safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics and clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and BI 1701963 is a SOS1 pan-KRAS inhibitor.
Conditions
- Advanced Cancer
- Metastatic Cancer
- Malignant Neoplasm of Colon
- Malignant Neoplasm of Lung
- Malignant Neoplastic Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRTX849 | KRAS G12C inhibitor |
| DRUG | BI 1701963 | SOS1 Inhibitor |
Timeline
- Start date
- 2021-07-28
- Primary completion
- 2022-11-02
- Completion
- 2022-11-15
- First posted
- 2021-07-23
- Last updated
- 2024-12-16
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04975256. Inclusion in this directory is not an endorsement.